Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Liwa Younis

Cardiovascular Disease St Louis, MO Medical Doctor

NPI 1588611305 CMS profile 71703

10012 Kenerly Road, Suite 301, St Louis, MO 63128

Open in the dashboard

General payments

$1,360

71 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$589,709 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Liwa Younis of St Louis, MO is reported in the CMS Open Payments database as having received $1,360 across 71 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $589,709 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 43rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $147 1
2023 General $117 6
2022 General $388 17
2021 General $342 23
2020 General $55 4
2019 General $312 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Liwa Younis
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Liwa Younis were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Liwa Younis Cardiovascular Disease median Middle half National median
2019 $312 $450 $127–$1,392 $163
2020 $55 $242 $77–$751 $114
2021 $342 $335 $101–$1,037 $132
2022 $388 $395 $121–$1,211 $149
2023 $117 $443 $136–$1,283 $160
2024 $147 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $267 17 payments
  2. Medtronic, Inc. $158 1 payment
  3. Merck Sharp & Dohme Corporation $151 9 payments
  4. Boston Scientific Corporation $147 1 payment
  5. Janssen Pharmaceuticals, Inc $138 10 payments
  6. Amarin Pharma Inc. $137 10 payments
  7. Sanofi-Aventis U.S. LLC $96 6 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $84 7 payments
  9. Amgen Inc. $52 3 payments
  10. Gilead Sciences, Inc. $39 2 payments
  11. Other $91 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,360 71 payments
Products named General payments · program years 2019–2024
  1. ENTRESTO Cardiovascular $187 13 payments
  2. Micra $158 1 payment
  3. VERQUVO $151 9 payments
  4. Intracept $147 1 payment
  5. XARELTO $138 10 payments
  6. Vascepa $111 8 payments
  7. LifeVest $84 7 payments
  8. ENTRESTO Cardiology/Vascular Diseases $63 3 payments
  9. Repatha $52 3 payments
  10. LEQVIO $47 3 payments
  11. Other $287 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,326

Median for Cardiology: 2,533

Drug cost

$148,238

Median for Cardiology: $485,213

Branded share of claims

33.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 88 $67,868
Xarelto Rivaroxaban Brand 41 $26,302
Entresto Sacubitril/Valsartan Brand 21 $15,770
Repatha Sureclick Evolocumab Brand 23 $15,533
Brilinta Ticagrelor Brand 19 $12,046
Ranolazine Er Ranolazine Brand 31 $2,627
Metoprolol Succinate Generic 74 $883
Clopidogrel Clopidogrel Bisulfate Brand 104 $877
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 113 $846
Rosuvastatin Calcium Generic 81 $649

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$42,240

Medicare's payments for the services billed

Medicare patients

422

Average age 75

Services billed

1,052

220 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 53%
Arthritis 53%
Ischemic heart disease 52%
Diabetes 43%
Chronic kidney disease 42%
Atrial fibrillation 40%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record